Rita Chiari
University of Perugia
CancerInternal medicineOncologyROS1Lung cancerChemotherapyImmunotherapynon-small cell lung cancer (NSCLC)CrizotinibEpidermal growth factor receptorNivolumabProgression-free survivalAdenocarcinomaKRASLorlatinibNon small cellIn patientCancer researchMedicineImmune system
229Publications
33H-index
3,637Citations
Publications 236
Newest
#1Silvia Novello (UNITO: University of Turin)H-Index: 73
#2Valter Torri (Mario Negri Institute for Pharmacological Research)H-Index: 86
Last. G. V. Scagliotti (UNITO: University of Turin)H-Index: 25
view all 36 authors...
Background null Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In this investigator-initiated study we aimed to evaluate the predictive utility of the messenger RNA (mRNA) expression levels of excision repair cross complementation group 1 (ERCC1) and thymidylate synthase (TS) as assessed in resected tumor. null null null Patients and methods null Seven hundred and seventy-three completely ...
Source
#1Luca Cantini (Marche Polytechnic University)H-Index: 9
#2Giulia Mentrasti (Marche Polytechnic University)H-Index: 5
Last. Alessandro MorabitoH-Index: 47
view all 39 authors...
Source
#1Martina Lorenzi (UNIPD: University of Padua)H-Index: 2
#2Alessandra Ferro (UNIPD: University of Padua)H-Index: 6
Last. Rita ChiariH-Index: 33
view all 22 authors...
LESSONS LEARNED Osimertinib has confirmed effectiveness in this real-world population of patients with EGFR-mutant advanced non-small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain metastases, and symptoms at diagnosis seem to have a worse prognosis. BACKGROUND Osimertinib became the standard treatment for patients with untreated EGF...
Source
#1Antonio RussoH-Index: 103
#2Lorena Incorvaia (University of Palermo)H-Index: 17
Last. Ada Maria Florena (University of Palermo)H-Index: 27
view all 21 authors...
Abstract null null The personalized medicine is in a rapidly evolving scenario. The identification of actionable mutations is revolutionizing the therapeutic landscape of tumors. The morphological and histological tumor features are enriched by the extensive genomic profiling, and the first tumor-agnostic drugs have been approved regardless of tumor histology, guided by predictive and druggable genetic alterations. This new paradigm of “mutational oncology”, presents a great potential to change ...
Source
#1Alessio CortelliniH-Index: 20
#2Domenico MallardoH-Index: 15
Last. Alain GelibterH-Index: 25
view all 20 authors...
Source
Source
Background: By the end of 2020, coronavirus disease 2019 (COVID-19) would have indelibly marked the cancer care setting. With Italy at the forefront of pandemic, unprecedented measures were adopted to tackle the quality care issue. As a result of pausing screening programs, diagnostic delays might affect the years to come. Aim of our multicenter Italian study is to evaluate whether the COVID-19 outbreak has impacted on likelihood of receiving timely diagnosis, staging and treatment for colorecta...
Source
#1Marco Russano (Università Campus Bio-Medico)H-Index: 16
#2Alessio Cortellini (University of L'Aquila)H-Index: 20
Last. Michele De TursiH-Index: 20
view all 50 authors...
The prognostic relevance of early immune-related adverse events (irAEs) in patients affected by non-small cell lung cancer (NSCLC) upon immunotherapy is not fully understood. The Leading to Treatment Discontinuation cohort included 24 patients experiencing severe irAEs after one of two administrations of single anti-PD-1/PD-L1 in any line setting for metastatic NSCLC between November 2015 and June 2019. The control cohort was composed of 526 patients treated with single anti-PD-1/PD-L1 in any li...
Source
#1Sara BaglivoH-Index: 14
#2Fortunato BianconiH-Index: 15
Last. Annamaria SiggillinoH-Index: 10
view all 17 authors...
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of lung cancer. However, their clinical benefit is limited to a minority of patients. To unravel immune-related factors that are predictive of sensitivity or resistance to immunotherapy, we performed a gene expression analysis by RNA-Seq using the Oncomine Immuno Response Assay (OIRRA) on a total of 33 advanced NSCLC patients treated with ICI evaluating the expression levels of 365 immune-related genes. We found four genes (CD...
Source
#1Daniele Santini (Università Campus Bio-Medico)H-Index: 78
#2Tea Zeppola (Università Campus Bio-Medico)H-Index: 9
Last. Vincenzo Adamo (UNIME: University of Messina)H-Index: 30
view all 48 authors...
BACKGROUND The favourable safety profile and the increasing confidence with immune checkpoint inhibitors (ICIs) might have boosted their prescription in frail patients with short life expectancies, who usually are not treated with standard chemotherapy. METHODS The present analysis aims to describe clinicians' attitudes towards ICIs administration during late stages of life within a multicenter cohort of advanced cancer patients treated with single agent PD-1/PD-L1 checkpoint inhibitors in Italy...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.